KRAS and neoplasm: Both 1-2C and 3-2E TCR-T cells could specifically respond to varied tumor cells with the KRAS-G12V mutation, indicating specific recognition of the TCRs to endogenously processed KRAS-G12V-9 peptide in tumor cells.